Telix Pharmaceuticals (NASDAQ:TLX) has reached a critical clinical milestone with the dosing of the first patient in its pivotal Phase 3 IPAX BrIGHT trial.
The procedure took place between April 14 and 15, 2026, at Austin Health in Melbourne, Australia, marking the commencement of the definitive study for TLX101-Tx in patients with recurrent glioblastoma.
This aggressive form of brain cancer currently has limited therapeutic options, positioning the trial as a significant development in the neuro-oncology landscape.
The IPAX BrIGHT study is a global, multicenter, open-label trial designed to evaluate the efficacy and safety of TLX101-Tx in combination with the chemotherapy agent lomustine, compared to lomustine monotherapy.
A key component of the trial’s precision medicine approach is the use of TLX101-Px PET imaging to facilitate patient selection and assess therapeutic response.
With regulatory approvals already secured in Australia, Austria, Belgium, and the Netherlands, Telix is scaling the study across international jurisdictions to validate the potential of its targeted radiation therapy in addressing high-grade gliomas.